Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.

Watson-Jones, Deborah; Changalucha, John; Whitworth, Hilary; Pinto, Ligia; Mutani, Paul; Indangasi, Jackton; Kemp, Troy; Hashim, Ramadhan; Kamala, Beatrice; Wiggins, Rebecca; +13 more... Songoro, Twaib; Connor, Nicholas; Mbwanji, Gladys; Pavon, Miquel A; Lowe, Brett; Mmbando, Devis; Kapiga, Saidi; Mayaud, Philippe; de SanJosé, Silvia; Dillner, Joakim; Hayes, Richard J; Lacey, Charles J; Baisley, Kathy; (2022) Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. The Lancet Global health, 10 (10). e1473-e1484. ISSN 2214-109X DOI: https://doi.org/10.1016/S2214-109X(22)00309-6

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S2214-109X(22)00309-6

Abstract

Share

Download

Filename: Jones_etal_2022_Immunogenicity-and-safety-of-one.pdf

Licence: Creative Commons: Attribution 4.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar